Reports

Sale

North America Herpes Simplex Virus Treatment Market

North America Herpes Simplex Virus Treatment Market Size: By Type: Herpes Simples Virus-1 Infection, Herpes Simplex Virus-2 Infection, Others; By Drug Type: Acyclovir, Valacyclovir, Famciclovir, Others; By Route of Administration: Oral, Parenteral, Topical; Regional Analysis; Market Dynamics; Supplier Landscape; 2024-2032

North America Herpes Simplex Virus Treatment Market Size

The North America herpes simplex virus treatment market was valued at USD 563.2 million in 2023, driven by increased funding to advance herpes simplex virus research in the region. The market is expected to grow at a CAGR of 7.50% during the forecast period of 2024-2032, with the values likely to rise from USD 605.4 million in 2024 to USD 1079.8 million by 2032.

 

North America Herpes Simplex Virus Treatment Market Outlook

  • In the United States, herpes simplex virus (HSV) 1 and 2 are considered the most common viral infections. This rising disease burden directly impacts the market demand for effective treatments.
  • Increased funding and initiatives to advance herpes simplex virus research are the major market trends.
  • The growing emphasis on the development of innovative treatments such as gene therapy to permanently cure this contagious viral infection is influencing the market share.

 

North America Herpes Simplex Virus Treatment Market Analysis

Herpes simplex virus (HSV) or herpes is a treatable infection that can cause painful ulcers or blisters. Type 1 (HSV-1) and Type 2 (HSV-2) are two types of herpes simplex virus. Anti-HSV medications such as acyclovir, famciclovir, and valacyclovir, are generally prescribed to prevent the virus from multiplying. Oral pain relievers (paracetamol or ibuprofen) and topical pain relievers (benzocaine, L-lysine, and docosanol) are often taken to manage pain. Heightened patient awareness surrounding herpes is leading to higher diagnosis rates, which contributes to the expansion of the global herpes simplex virus treatment market. Further, the increasing focus on the development of innovative treatments such as gene therapy to permanently cure the infection is expected to drive the North America herpes simplex virus treatment market growth.

 

In the United States, herpes simplex virus (HSV) 1 and 2 are considered the most common viral infections. Around 80% of individuals between the ages of 14 and 49 are affected by HSV-1 and over 10% are infected with HSV-2.  To date, there are no HSV vaccines approved by the US Food and Drug Administration and current treatment strategies are ineffective against latent HSV infections. To accelerate the development of vaccines, therapeutics, and diagnostics against herpes, the National Institutes of Health (NIH) established the Strategic Plan for Herpes Simplex Virus Research 2023-2028, aligning with the Sexually Transmitted Infections (STI) National Strategic Plan. The NIH HSV research plan states 4 priorities: increase knowledge of HSV biology, improve diagnosis, enhance treatment strategies, and advance research to prevent this viral infection. Such initiatives are likely to expedite the introduction of novel interventions, which will directly impact the North America herpes simplex virus treatment market demand.

 

One of the major market trends is the rising funding for herpes simplex virus research with the aim of reducing the associated health consequences. In October 2023, infectious disease company, Rational Vaccines, Inc. (RVx) announced that it had received USD 2.8 million in funding from the National Institute of Health (NIH) to boost its research in the treatment, diagnosis, and prevention of the herpes simplex virus infection. The company was awarded three separate grants to further its development of highly sensitive HSV-type-specific tests, live-attenuated HSV-1 strain ‘VC2’ to prevent and treat ocular herpes, and prophylactic and therapeutic HSV vaccines to curb the spread of herpes. Increased investment to stimulate advancements in herpes simplex virus testing and treatments is poised to augment the market share.

 

North America Herpes Simplex Virus Treatment Market Segmentation

The report offers a detailed analysis of the market based on the following segments:

 

Market Breakup Categories
Type Herpes Simplex Virus-1 Infection, Herpes Simplex Virus-2 Infection, Others
Drug Type Herpes Simplex Virus-1 Infection, Herpes Simplex Virus-2 Infection, Others
Route of Administration Oral, Parenteral, Topical
Country United States, Canada

 

Leading Players in the North America Herpes Simplex Virus Treatment Market

The key features of the market report include clinical trials analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 

Roche Holding AG

F. Hoffmann-La Roche AG, a global pioneer in pharmaceuticals and diagnostics, is actively involved in developing serology and molecular assays to provide testing and result interpretation of herpes simplex virus infections.

 

AbbVie Inc.

The global biopharmaceutical company AbbVie Inc. is involved in the clinical development of treatments intended for combating viral infections.

 

Johnson & Johnson

Johnson & Johnson Innovative Medicine is known for heavily investing in its research initiatives to develop therapeutics and vaccines for the treatment and prevention of life-threatening infectious diseases.

 

GlaxoSmithKline plc

GlaxoSmithKline plc, a British multinational pharmaceutical company headquartered in London, is conducting a clinical trial to evaluate its targeted immunotherapy (GSK3943104A) efficacy against HSV infections.

 

Other players in the market include Sanofi, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Merck & Co., Inc., and Pfizer Inc.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Drug Type
  • Route of Administration
  • Region
Breakup by Type
  • Herpes Simples Virus-1 Infection
  • Herpes Simplex Virus-2 Infection
  • Others
Breakup by Drug Type
  • Acyclovir
  • Valacyclovir
  • Famciclovir
  • Others
Breakup by Route of Administration
  • Oral
  • Parenteral
  • Topical
Breakup by Region
  • United States
  • Canada
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Roche Holding AG
  • AbbVie Inc.
  • Johnson & Johnson
  • GlaxoSmithKline plc
  • Sanofi
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Merck & Co., Inc.
  • Pfizer Inc. 

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    North America  Herpes Simplex Virus Treatment Market Overview 

    3.1    North America Herpes Simplex Virus Treatment Market Historical Value (2017-2023) 
    3.2    North America Herpes Simplex Virus Treatment Market Forecast Value (2024-2032)
4    Vendor Positioning Analysis
    4.1    Key Vendors
    4.2    Prospective Leaders
    4.3    Niche Leaders
    4.4    Disruptors
5    North America  Herpes Simplex Virus Treatment Market Landscape*
    5.1    North America Herpes Simplex Virus Treatment: Developers Landscape
        5.1.1    Analysis by Year of Establishment
        5.1.2    Analysis by Company Size
        5.1.3    Analysis by Region
    5.2    North America Herpes Simplex Virus Treatment: Product Landscape
        5.2.1    Analysis by Type    
        5.2.2    Analysis by Drug Type
6    North America Herpes Simplex Virus Treatment Market Dynamics
    6.1    Market Drivers and Constraints
    6.2    SWOT Analysis
        6.2.1    Strengths
        6.2.2    Weaknesses
        6.2.3    Opportunities
        6.2.4    Threats
    6.3    PESTEL Analysis 
        6.3.1    Political 
        6.3.2    Economic 
        6.3.3    Social 
        6.3.4    Technological 
        6.3.5    Legal 
        6.3.6    Environment
    6.4    Porter’s Five Forces Model
        6.4.1    Bargaining Power of Suppliers
        6.4.2    Bargaining Power of Buyers
        6.4.3    Threat of New Entrants
        6.4.4    Threat of Substitutes
        6.4.5    Degree of Rivalry
    6.5    Key Demand Indicators 
    6.6    Key Price Indicators
    6.7    Industry Events, Initiatives, and Trends  
    6.8    Value Chain Analysis
7    North America Herpes Simplex Virus Treatment Market Segmentation (2017-2032)
    7.1    North America Herpes Simplex Virus Treatment Market (2017-2032) by Type
        7.1.1    Market Overview
        7.1.2    Herpes Simples Virus-1 Infection
        7.1.3    Herpes Simplex Virus-2 Infection
        7.1.4    Others
    7.2    North America Herpes Simplex Virus Treatment Market (2017-2032) by Drug Type
        7.2.1    Market Overview
        7.2.2    Acyclovir
        7.2.3    Valacyclovir
        7.2.4    Famciclovir
        7.2.5    Others
    7.3    North America Herpes Simplex Virus Treatment Market (2017-2032) by Route of Administration
        7.3.1    Market Overview
        7.3.2    Oral
        7.3.3    Parenteral
        7.3.4    Topical
    7.4    North America Herpes Simplex Virus Treatment Market (2017-2032) by Country
        7.4.1    Market Overview
        7.4.2    United States
        7.4.3    Canada
8    United States  Herpes Simplex Virus Treatment Market (2017-2032)
    8.1    United States Herpes Simplex Virus Treatment Market (2017-2032) by Type
        8.1.1    Market Overview    
        8.1.2    Herpes Simples Virus-1 Infection
        8.1.3    Herpes Simplex Virus-2 Infection
        8.1.4    Others
    8.2    United States Herpes Simplex Virus Treatment Market (2017-2032) by Drug Type
        8.2.1    Market Overview
        8.2.2    Acyclovir
        8.2.3    Valacyclovir
        8.2.4    Famciclovir
        8.2.5    Others 
    8.3    United States Herpes Simplex Virus Treatment Market (2017-2032) by Route of Administration
        8.3.1    Market Overview
        8.3.2    Oral
        8.3.3    Parenteral
        8.3.4    Topical 
9    Canada Herpes Simplex Virus Treatment Market (2017-2032)
    9.1    Canada Herpes Simplex Virus Treatment Market (2017-2032) by Type
        9.1.1    Market Overview    
        9.1.2    Herpes Simples Virus-1 Infection
        9.1.3    Herpes Simplex Virus-2 Infection
        9.1.4    Others
    9.2    Canada Herpes Simplex Virus Treatment Market (2017-2032) by Drug Type
        9.2.1    Market Overview
        9.2.2    Acyclovir
        9.2.3    Valacyclovir
        9.2.4    Famciclovir
        9.2.5    Others
    9.3    Canada Herpes Simplex Virus Treatment Market (2017-2032) by Route of Administration
        9.3.1    Market Overview
        9.3.2    Oral
        9.3.3    Parenteral
        9.3.4    Topical 
10    Regulatory Framework
    10.1     FDA
11    Clinical Trial Analysis
    11.1    Analysis by Trial Registration Year
    11.2    Analysis by Trial Status
    11.3    Analysis by Trial Phase
    11.4    Analysis by Therapeutic Area
    11.5    Analysis by Geography
12    Grant Analysis
    12.1    Analysis by Year
    12.2    Analysis by Amount Awarded
    12.3    Analysis by Issuing Authority
    12.4    Analysis by Grant Product
    12.5    Analysis by Funding Institute
    12.6    Analysis by Departments
    12.7    Analysis by Recipient Organization
13    Funding and Investment Analysis
    13.1     Analysis by Funding Instances
    13.2     Analysis by Type of Funding
    13.3     Analysis by Funding Amount
    13.4     Analysis by Leading Players
    13.5     Analysis by Leading Investors
    13.6     Analysis by Geography
14    Strategic Initiative
    14.1     Analysis by Partnership Instances
    14.2     Analysis by Type of Partnership
    14.3     Analysis by Leading Players
    14.4     Analysis by Geography
15    Supplier Landscape
    15.1     Market Share Analysis, By Region (Top 5 Companies)
        15.1.1    Market Share Analysis: North America
    15.2    Roche Holding AG
        15.2.1    Financial Analysis
        15.2.2    Product Portfolio
        15.2.3    Demographic Reach and Achievements
        15.2.4    Mergers and Acquisitions
        15.2.5    Certifications 
    15.3    AbbVie Inc.
        15.3.1    Financial Analysis
        15.3.2    Product Portfolio
        15.3.3    Demographic Reach and Achievements
        15.3.4    Mergers and Acquisitions
        15.3.5    Certifications
    15.4    Johnson & Johnson
        15.4.1    Financial Analysis
        15.4.2    Product Portfolio
        15.4.3    Demographic Reach and Achievements
        15.4.4    Mergers and Acquisitions
        15.4.5    Certifications
    15.5    GlaxoSmithKline plc
        15.5.1    Financial Analysis
        15.5.2    Product Portfolio
        15.5.3    Demographic Reach and Achievements
        15.5.4    Mergers and Acquisitions
        15.5.5    Certifications
    15.6    Sanofi 
        15.6.1    Financial Analysis
        15.6.2    Product Portfolio
        15.6.3    Demographic Reach and Achievements
        15.6.4    Mergers and Acquisitions
        15.6.5    Certifications
    15.7    Mylan N.V.
        15.7.1    Financial Analysis
        15.7.2    Product Portfolio
        15.7.3    Demographic Reach and Achievements
        15.7.4    Mergers and Acquisitions
        15.7.5    Certifications
    15.8    Teva Pharmaceutical Industries Ltd.
        15.8.1    Financial Analysis
        15.8.2    Product Portfolio
        15.8.3    Demographic Reach and Achievements
        15.8.4    Mergers and Acquisitions
        15.8.5    Certifications
    15.9    Novartis AG
        15.9.1    Financial Analysis
        15.9.2    Product Portfolio
        15.9.3    Demographic Reach and Achievements
        15.9.4    Mergers and Acquisitions
        15.9.5    Certifications
    15.10    Merck & Co., Inc.
        15.10.1    Financial Analysis
        15.10.2    Product Portfolio
        15.10.3    Demographic
        15.10.4    Mergers and Acquisitions
        15.10.5    Certifications
    15.11    Pfizer Inc. 
        15.11.1    Financial Analysis
        15.11.2    Product Portfolio
        15.11.3    Demographic Reach and Achievements
        15.11.4    Mergers and Acquisitions
        15.11.5    Certifications
16    North America Herpes Simplex Virus Treatment Market – Distribution Model (Additional Insight)
    16.1     Overview 
    16.2     Potential Distributors 
    16.3     Key Parameters for Distribution Partner Assessment 
17    Key Opinion Leaders (KOL) Insights (Additional Insight)
18    Payment Methods (Additional Insight)

    18.1     Government Funded
    18.2     Private Insurance
    18.3     Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

 

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

 

**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.

Key Questions Answered in the Report

The market attained a value of about USD 563.2 million in 2023 driven by the increasing research and development activities in the region.

The market is anticipated to grow at a CAGR of 7.50% during the forecast period of 2024-2032, likely to reach a market value of USD 1079.8 million by 2032.

The rising prevalence of herpes simplex virus infections and increasing healthcare expenditure are fuelling the demand for the market.

One of the significant trends in the market is the increased funding for herpes simplex virus research. In October 2023, Rational Vaccines, Inc. (RVx) announced that it had received USD 2.8 million in funding from the National Institute of Health (NIH) to boost its research in the treatment, diagnosis, and prevention of the herpes simplex virus infection.

Based on the type, the market is segmented into herpes simplex virus-1 infection, and herpes simplex virus-2 infection, among others.

By drug type, the market is divided into Acyclovir, Valacyclovir, and Famciclovir, among others.

The market breakup by route of administration includes oral, parenteral, and topical.

The market segmentation by countries includes the United States and Canada. 

The key players in the market are Roche Holding AG, AbbVie Inc., Johnson & Johnson, GlaxoSmithKline plc, Sanofi, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Merck & Co., Inc., and Pfizer Inc.

Purchase Full Report

Mini Report

$ 2639     $2399
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 4399     $3999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 5829     $5299
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 6929     $6299
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER